

August 1, 2019



# Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019

**-- Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET --**

ROCKVILLE, Md., Aug. 1, 2019 /PRNewswire/ -- [Synthetic Biologics, Inc.](#) (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights and financial results for the quarter ended June 30, 2019 on Thursday, August 8, 2019, and to host a conference call the same day at 4:30 p.m. ET. The dial-in information for the call is as follows:



U.S. (toll free): 1-888-347-5280  
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at <https://www.webcaster4.com/Webcast/Page/1096/31274>. An archived replay of the call will be available for approximately ninety (90) days at the same URL, <https://www.webcaster4.com/Webcast/Page/1096/31274> beginning approximately one hour after the call's conclusion.

**About Synthetic Biologics, Inc.**

Synthetic Biologics, Inc. (NYSE American: SYN) is a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, *C. difficile* infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) designed to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at [www.syntheticbiologics.com](http://www.syntheticbiologics.com).

🔗 View original content to download multimedia <http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2019-second-quarter-operational-highlights-and-financial-results-on-august-8-2019-300894689.html>

SOURCE Synthetic Biologics, Inc.